Antonio Vidal-Puig

Antonio Vidal-Puig (born Valencia, Spain June 12, 1962) is a Spanish medical doctor and scientist who works as a Professor of Molecular Nutrition and Metabolism at the University of Cambridge (UK), best known for advancing the concept that pharmacological targeting of brown fat may serve to treat overweight and obesity in affected individuals,[1] as well as for introducing the concept of adipose tissue "expandability" as an important factor in the pathogenesis of insulin resistance in the context of positive energy balance.

[12] His academic engagements outside the UK include his affiliation with the Centre on Artificial Intelligence for Humankind at the National University of Singapore Business School.

As a visiting professor at Nanjing University, he is engaged in studies concerning aspects of the epidemic of obesity and diabetes occurring in China.

[2] Novel concepts worked on by Vidal-Puig include: Research articles where Vidal-Puig is an author will be found in current entries on Adipogenesis, Gene expression profiling, Lipidomics, Lipotoxicity, Macrophages, Metabolic syndrome, Metabolomics, Mitophagy, Nicotinamide phosphoribosyltransferase, Non-alcoholic fatty liver disease, Pyruvate carboxylase, Resistin, Senotherapy, Stearoyl-CoA desaturase-1, Uncoupling protein, UCP2, and UCP3.

[citation needed] Notable Cambridge scientists with whom Vidal-Puig has shared paper authorship include Krishna Chatterjee, Sadaf Farooqi, Nita Forouhi, Giles Yeo, Stephen O'Rahilly, and Nick Wareham.